In 2015, Chen et al. [19] found that FEZF1 antisense RNA1 (FEZF1-AS1) was upregulated in CRC tissues and could serve as a potential therapeutic target in CRC. The gene discussed is FEZF1; the disease is colorectal carcinoma.